Average Co-Inventor Count = 4.63
ph-index = 2
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Dana-farber-cancer Institute Inc. (10 from 1,209 patents)
2. Fundacion Sales (5 from 8 patents)
3. Consejo Nacional De Investigaciones Cientificas Y Tecnicas (conicet) (4 from 74 patents)
4. The Brigham and Women's Hospital, Inc. (3 from 1,373 patents)
5. The Broad Institute, Inc. (1 from 443 patents)
6. Conicet (1 from 2 patents)
10 patents:
1. 11723972 - Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
2. 11673956 - Anti-galectin-1 (Gal1) monoclonal antibodies and fragments thereof for neutralizing Gal1
3. 10948492 - PD-L2 biomarkers predictive of PD-1 pathway inhibitor responses in esophagogastric cancers
4. 10844126 - Anti-galectin-1 (GAL1) monoclonal antibodies and fragments thereof for neutralizing GAL1
5. 10519238 - Anti-galectin-1 monoclonal antibodies and fragments thereof
6. 10456465 - Compositions, kits, and methods for the diagnosis prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
7. 9939428 - Compositions, kits, and methods for the diagnosis, prognosis, and monitoring of immune disorders using galectin-1
8. 9890429 - Compositions, kits, and methods for the identification, assessment, prevention, and therapy of cancer
9. 9206427 - Compositions, kits, and methods for the modulation of immune responses using galectin-1
10. 8968740 - Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1